Massachusetts-based AI pharmaceutical company Ventus Therapeutics has raised USD 140 million in a Series C funding round co-led by Softbank Vision Fund 2 and RA Capital Management. Others include founding investor Versant Ventures, GV, and Qatar Investment Authority. The round follows the company’s recent USD 100 million Series B funding round in April 2021.
The proceeds will be directed toward further developing the company’s computational platform ReSOLVE by improving its machine learning capabilities as well as advancing three of its lead drug programs toward the investigational new drug (IND) stage by 2023. It also intends to build large proprietary virtual libraries.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.